CA-CRATEDB
1.3.2023 14:16:17 CET | Business Wire | Press release
CrateDB, the distributed SQL database company enabling data insights at scale, is pleased to announce the appointment of Lars Färnström as new Chief Executive Officer (CEO). With expansive leadership experience across the software sector, Lars is tasked with taking CrateDB into a new phase of growth as it looks to deliver data-driven decision making to global enterprises.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005068/en/
Real-Time Analytics Database Company CrateDB Names Lars Färnström as New CEO (Photo: Business Wire)
Lars Färnström, CEO, CrateDB - “I am thrilled to join the talented team at CrateDB and help drive the next phase of growth for this innovative database company. CrateDB addresses the urgent need for companies to make data driven decisions in real-time and leverage the power of insight that AI/ML can bring.”
“CrateDB is unique in this sense it allows developers, data engineers and data scientists to use standard SQL to access and query time series data, relational data, semi-structured data, complex files like JSONs, geo-spatial, full text and blobs. CrateDB stores all this critical data in a single unified database and delivers results in real-time, at a scale and with low costs – on-premise, in the cloud and at the Edge. These are unique capabilities any company needs to remain competitive.”
“We are incredibly pleased to announce Lars as our new CEO. After speaking with Lars about his experience and vision for CrateDB, we knew immediately that he is the person to take the company forward. Lars’ knowledge of the software sector, and in particular the ability for data to transform how enterprises operate, will be hugely significant for CrateDB.” - Alois Flatz, Chairman of the Board, CrateDB.
Lars Färnström has more than 25 years of experience in the software industry, where he has held a variety of senior and executive positions in management, sales, marketing, product marketing and program management. He joins CrateDB from C3.ai where he was responsible for the Nordics, Benelux, and Switzerland. Prior to C3.ai, he worked for small, medium, and large enterprises such as HPE, Siebel Systems, GoodData, and Board International where he helped scale their businesses.
For more information about CrateDB, visit www.crate.io.
ENDS
About CrateDB
CrateDB is a real-time analytics database solution, enabling data insights at scale. CrateDB’s ability to ingest and manage massive amounts of data from diverse sources empowers companies worldwide to turn data into business value.
CrateDB was founded in 2013 and operates globally with offices in Germany, Austria, Switzerland and the US. In 2021, CrateDB was named as an Honorable Mention in the 2021 Gartner Magic Quadrant for Cloud Database Management Systems and won the IoT Evolution Industrial IoT Product of the Year Award. Clients maximizing their data potential with CrateDB include ABB, Alpla, Rauch, TGW Logistics, and Bitmovin.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005068/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom